China Shineway Pharmaceutical Group Limited (C1S) - Cash Flow Conversion Efficiency
Based on the latest financial reports, China Shineway Pharmaceutical Group Limited (C1S) has a cash flow conversion efficiency ratio of 0.024x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€160.69 Million ≈ $187.86 Million USD) by net assets (€6.64 Billion ≈ $7.76 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of China Shineway Pharmaceutical Group Limi to measure how much of total assets are equity-financed.
China Shineway Pharmaceutical Group Limited - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how China Shineway Pharmaceutical Group Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check China Shineway Pharmaceutical Group Limi (C1S) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
China Shineway Pharmaceutical Group Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of China Shineway Pharmaceutical Group Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Magic Software Enterprises Ltd
TA:MGIC
|
0.064x |
|
Daoming Optics&Chemical Co Ltd
SHE:002632
|
0.058x |
|
Jiangsu LiXing General Steel Ball Co Ltd
SHE:300421
|
0.009x |
|
GH RESEARCH PLC DL-025
F:1KA
|
N/A |
|
Nuveen Select Tax-Free Income Portfolio
NYSE:NXP
|
-0.002x |
|
Yang Guang Co Ltd
SHE:000608
|
0.008x |
|
Burelle SA
PA:BUR
|
0.141x |
|
Obsidian Energy Ltd
TO:OBE
|
0.029x |
Annual Cash Flow Conversion Efficiency for China Shineway Pharmaceutical Group Limited (2013–2025)
The table below shows the annual cash flow conversion efficiency of China Shineway Pharmaceutical Group Limited from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see C1S stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €8.06 Billion ≈ $9.43 Billion |
€1.17 Billion ≈ $1.37 Billion |
0.145x | +12.71% |
| 2024-12-31 | €7.47 Billion ≈ $8.73 Billion |
€963.13 Million ≈ $1.13 Billion |
0.129x | -2.71% |
| 2023-12-31 | €7.03 Billion ≈ $8.22 Billion |
€932.63 Million ≈ $1.09 Billion |
0.133x | -23.75% |
| 2022-12-31 | €6.38 Billion ≈ $7.46 Billion |
€1.11 Billion ≈ $1.30 Billion |
0.174x | +45.92% |
| 2021-12-31 | €5.90 Billion ≈ $6.90 Billion |
€703.15 Million ≈ $822.06 Million |
0.119x | +8.11% |
| 2020-12-31 | €5.79 Billion ≈ $6.77 Billion |
€638.57 Million ≈ $746.55 Million |
0.110x | +73.01% |
| 2019-12-31 | €5.78 Billion ≈ $6.75 Billion |
€368.00 Million ≈ $430.23 Million |
0.064x | -31.04% |
| 2018-12-31 | €5.77 Billion ≈ $6.74 Billion |
€532.59 Million ≈ $622.65 Million |
0.092x | +9.59% |
| 2017-12-31 | €5.82 Billion ≈ $6.81 Billion |
€490.65 Million ≈ $573.62 Million |
0.084x | -35.34% |
| 2016-12-31 | €5.63 Billion ≈ $6.58 Billion |
€733.53 Million ≈ $857.57 Million |
0.130x | -7.29% |
| 2015-12-31 | €5.30 Billion ≈ $6.19 Billion |
€744.71 Million ≈ $870.64 Million |
0.141x | -11.01% |
| 2014-12-31 | €4.89 Billion ≈ $5.72 Billion |
€773.16 Million ≈ $903.90 Million |
0.158x | +34.64% |
| 2013-12-31 | €4.43 Billion ≈ $5.18 Billion |
€519.89 Million ≈ $607.80 Million |
0.117x | -- |
About China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules … Read more